Search results for "LOD"

showing 10 items of 4833 documents

Juvenile migraine and allodynia: results of a retrospective study.

2015

Background There are only 2 small sample studies investigating allodynia in the pediatric population. The aim of this study was to evaluate the frequency of allodynia during cephalalgic attacks in a juvenile population with primary headaches and its association with other symptoms of migraine. Methods We reviewed all medical records of patients with primary headache consecutively seen during a 2-year period. Frequency of allodynia was evaluated, by means of a questionnaire, consisting of 6 questions (for example: Do you avoid touching your head when you have a migraine attack?). Results Two hundred thirty children suffering from primary headache were seen during the study period. Two hundre…

AdultMalemedicine.medical_specialtyAdolescentDatabases FactualNauseaMigraine DisordersPopulationMotor ActivitySensitivity and SpecificityYoung AdultchildrenphonophobiaInternal medicineSurveys and QuestionnairesmedicineHumansmigraineLongitudinal StudieseducationallodyniaRetrospective Studieseducation.field_of_studybusiness.industryprimary headacheReproducibility of ResultsRetrospective cohort studyNauseaOdds ratiomedicine.diseaseConfidence intervalPhonophobiaAllodyniaNeurologyMigraineHyperalgesiaAnesthesiaMultivariate AnalysisSettore MED/26 - NeurologiaFemaleNeurology (clinical)medicine.symptombusinessHeadache
researchProduct

Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and h…

2000

Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter trial including 18 patients with refractory anemia with excess of blasts in transformation (RAEB-T), 86 patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndromes, and six patients with secondary AML after previous chemotherapy. Median age was 58 years (range: 18-76 years). Forty-nine patients (45%) achieved a complete remission (CR) after two induction cycles with idarubicin, ara-C, and etoposide, 52% of them aged/=60 years and 35% aged60 years (p=0.06). After two consolidation courses, patients were randomized to four cycles of either high-…

AdultMalemedicine.medical_specialtyAdolescentGastroenterologyInternal medicineMulticenter trialAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineIdarubicinProspective StudiesSurvival rateEtoposideAgedEtoposideDose-Response Relationship Drugbusiness.industryMyelodysplastic syndromesCytarabineHematologyGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival RateLeukemiaLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseCytarabineInterleukin-2FemaleImmunotherapyIdarubicinbusinessRefractory anemia with excess of blastsmedicine.drugAnnals of Hematology
researchProduct

Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, gra…

1996

Differentiation induction therapy is being tested in myelodysplastic syndromes to ameliorate maturation defects and to restore normal hematopoietic function. To this end, 17 patients (eight with refractory anemia, two with refractory anemia and ring sideroblasts, and seven with refractory anemia and excess of blast cells) were treated with a combination of all-trans-retinoic acid (ATRA), granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO), and alpha-tocopherol for durations of 8-16 weeks. Absolute neutrophil counts increased in all patients; platelet counts increased in five patients with discontinuation of transfusion needs in two of four transfusion-dependent patients. Sti…

AdultMalemedicine.medical_specialtyCombination therapyTretinoinBone Marrowhemic and lymphatic diseasesInternal medicineGranulocyte Colony-Stimulating FactorMedicineHumansVitamin EErythropoietinAgedAged 80 and overHematologybusiness.industryMyelodysplastic syndromesHematologyGeneral MedicineMiddle Agedmedicine.diseaseGranulocyte colony-stimulating factorBlood Cell CountHematopoiesisHaematopoiesisEndocrinologymedicine.anatomical_structureErythropoietinMyelodysplastic SyndromesErythropoiesisDrug Therapy CombinationFemaleBone marrowbusinessmedicine.drugAnnals of hematology
researchProduct

Inhibition of neutral endopeptidase (NEP) facilitates neurogenic inflammation

2005

Neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE) are involved in neuropeptide degradation and may modulate neurogenic inflammation. We therefore explored the effect of specific blockers of NEP and ACE on the intensity of neurogenic inflammation. We investigated eight subjects on three occasions. Two pairs of microdialysis fibers equipped with intraluminal wires were inserted intracutaneously into the volar forearms and electrical stimuli were delivered via the intraluminal electrodes. The microdialysis fibers were perfused either with normal saline, phosphoramidon (NEP inhibitor), or captopril (ACE inhibitor). CGRP release was assessed in the microdialysis eluate via a sp…

AdultMalemedicine.medical_specialtyMicrodialysisCaptoprilTime FactorsCalcitonin Gene-Related PeptideMicrodialysisPeptidyl-Dipeptidase AImmunoenzyme Techniqueschemistry.chemical_compoundDevelopmental NeuroscienceInternal medicineLaser-Doppler FlowmetrymedicineHumansDrug InteractionsEnzyme InhibitorsSkinNerve Fibers UnmyelinatedNeurogenic inflammationbiologyPhosphoramidonGlycopeptidesCaptoprilAngiotensin-converting enzymeElectric StimulationVasodilationAllodyniaEndocrinologyNeurologychemistryHyperalgesiaACE inhibitorHyperalgesiabiology.proteinFemaleNeprilysinNeurogenic Inflammationmedicine.symptommedicine.drugExperimental Neurology
researchProduct

Increased Risk of Acute Myeloid Leukemias and Myelodysplastic Syndromes in Patients Who Received Thiopurine Treatment for Inflammatory Bowel Disease.

2014

Background & Aims Treatment with immunosuppressive thiopurines such as azathioprine is associated with an increased risk of leukemogenesis. We assessed the risk of myeloid disorders, such as acute myeloid leukemia and myelodysplastic syndromes, in a large cohort of patients with inflammatory bowel disease (IBD) in France. Methods We performed a prospective observational study of 19,486 patients with IBD enrolled in the Cancers Et Surrisque Associe aux Maladies inflammatoires intestinales En France (CESAME) study from May 2004 through June 2005; patients were followed through December 31, 2007. The incidence of myeloid disorders in the general population, which was used for reference, was de…

AdultMalemedicine.medical_specialtyMyeloidAdolescentPopulationAzathioprineRisk AssessmentInflammatory bowel diseaseCohort StudiesYoung Adult[ CHIM.ORGA ] Chemical Sciences/Organic chemistryInternal medicinehemic and lymphatic diseasesAzathioprinemedicineHumansProspective Studieseducationeducation.field_of_studyCrohn's diseaseHepatologyThiopurine methyltransferasebiologybusiness.industry[CHIM.ORGA]Chemical Sciences/Organic chemistryIncidenceMyelodysplastic syndromesGastroenterologyMyeloid leukemiaMiddle AgedInflammatory Bowel Diseasesmedicine.disease3. Good healthLeukemia Myeloid Acutemedicine.anatomical_structureMyelodysplastic SyndromesImmunologybiology.proteinFemaleFrancebusinessImmunosuppressive Agentsmedicine.drug
researchProduct

Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia

2007

Patients with neutropenia resulting from chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal invasive fungal infections.In this randomized, multicenter study involving evaluators who were unaware of treatment assignments, we compared the efficacy and safety of posaconazole with those of fluconazole or itraconazole as prophylaxis for patients with prolonged neutropenia. Patients received prophylaxis with each cycle of chemotherapy until recovery from neutropenia and complete remission, until occurrence of an invasive fungal infection, or for up to 12 weeks, whichever came first. We compared the incidence of prove…

AdultMalemedicine.medical_specialtyPosaconazoleAntifungal AgentsNeutropeniaAdolescentItraconazolemedicine.medical_treatmentAntineoplastic AgentsKaplan-Meier EstimateOpportunistic InfectionsNeutropeniaInternal medicineClinical endpointmedicineHumansSingle-Blind MethodFluconazoleAgedAged 80 and overChemotherapyLeukopeniabusiness.industryMyelodysplastic syndromesGeneral MedicineMiddle AgedTriazolesmedicine.diseaseSurgeryLeukemia Myeloid AcuteTreatment OutcomeMycosesMyelodysplastic SyndromesFemaleItraconazolemedicine.symptombusinessFluconazolemedicine.drugNew England Journal of Medicine
researchProduct

Effects of amlodipine on renal haemodynamics in mild to moderate hypertensive patients. A randomized controlled study versus placebo.

1993

In this study the efficacy and safety of short-term amlodipine administration on renal haemodynamics were evaluated in mild to moderate hypertensive subjects. Our final goal was to evaluate whether the reduced blood pressure induced by treatment was associated with maintenance of renal function. After a run-in period with placebo, 30 hypertensive patients without cardiac or renal diseases were randomly allocated to a double-blind 4 weeks controlled study with amlodipine 10 mg once a day (15 patients) or placebo (15 patients). Renal haemodynamic measurements included effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) by radionuclide study using 131I-hippuran and 99mTc, w…

AdultMalemedicine.medical_specialtyRenal Blood Flow Effectivemedicine.medical_treatmentRenal functionPlacebolaw.inventionRandomized controlled trialDouble-Blind MethodlawReninmedicineHumansPharmacology (medical)AmlodipinePharmacologyChemotherapybusiness.industryGeneral MedicineMiddle AgedSurgeryClinical trialUrodynamicsBlood pressureAnesthesiaRenal blood flowHypertensionFemaleVascular ResistanceAmlodipinebusinessmedicine.drugGlomerular Filtration RateEuropean journal of clinical pharmacology
researchProduct

Hemisensory disturbances in patients with complex regional pain syndrome.

2018

Sensory disturbances often spread beyond the site of injury in complex regional pain syndrome (CRPS) but whether this applies equally to CRPS I and II, or changes across the course of the disease, is unknown. Establishing this is important, because different symptom profiles in CRPS I and II, or in acute vs chronic CRPS, might infer different pathophysiology and treatment approaches. To explore these questions, sensory disturbances were assessed in the limbs and forehead of 71 patients with CRPS I and 33 patients with CRPS II. Pain had persisted up to 12 months in 32 patients, for 13 to 36 months in 29 patients, and for longer than this in 43 patients. Patients with CRPS I were more likely …

AdultMalemedicine.medical_specialtySensory systemDiseasePerceptual Disorders03 medical and health sciencesYoung Adult0302 clinical medicinePhysical medicine and rehabilitation030202 anesthesiologymedicineHumansPain ManagementYoung adultAgedbusiness.industryMiddle Agedmedicine.diseasePathophysiologyAnesthesiology and Pain MedicineComplex regional pain syndromeNociceptionAllodyniaNeurologyHyperalgesiaHyperalgesiaFemaleNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgeryComplex Regional Pain SyndromesPain
researchProduct

Sulodexide versus calcium heparin in the medium-term treatment of deep vein thrombosis of the lower limbs.

1997

Thirty adult patients with distal, monolateral deep vein thrombosis of the lower limbs were randomly treated for sixty days either with subcutaneous Ca-Heparin or with Sulodexide, administered IM for ten days and orally for fifty days. The thrombus accretion above the knee, the venous pressures of the affected leg, the clinical sympto matology, and some laboratory coagulative tests were monitored throughout the admin istration period. Local tolerability of the two treatments was also evaluated.The two applied treatments evidenced a net antithrombotic activity, preventing thrombus accretion above the knee, improving with the same efficacy the venous pressures in the affected legs, and simila…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.drug_classDeep vein030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsHumansMedicine030212 general & internal medicineThrombusAgedGlycosaminoglycansmedicine.diagnostic_testHeparinbusiness.industryAnticoagulantHeparinMiddle AgedThrombophlebitismedicine.diseaseThrombosisSulodexideSurgerymedicine.anatomical_structureTolerabilityAnesthesiaSettore BIO/14 - FarmacologiaFemaleAdult Aged Female Fibrinolytic Agents/administration & dosage Fibrinolytic Agents/therapeutic use* Glycosaminoglycans/administration & dosage Glycosaminoglycans/therapeutic use* Heparin/therapeutic use* Humans Male Middle Aged Thrombophlebitis/drug therapy*Cardiology and Cardiovascular Medicinebusinessmedicine.drugPartial thromboplastin time
researchProduct

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with ac…

2019

Background: Further improvement of preparative regimens before allogeneic haemopoietic stem cell transplantation (HSCT) is an unmet medical need for the growing number of older or comorbid patients with acute myeloid leukaemia or myelodysplastic syndrome. We aimed to evaluate the efficacy and safety of conditioning with treosulfan plus fludarabine compared with reduced-intensity busulfan plus fludarabine in this population. Methods: We did an open-label, randomised, non-inferiority, phase 3 trial in 31 transplantation centres in France, Germany, Hungary, Italy, and Poland. Eligible patients were 18–70 years, had acute myeloid leukaemia in first or consecutive complete haematological remissi…

AdultMalemedicine.medical_specialtyTransplantation ConditioningPopulationMedizinAntineoplastic AgentsTreosulfanDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumanseducationBusulfanPreparative RegimenAgededucation.field_of_studybusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedInterim analysis3. Good healthFludarabineTransplantationRegimenLeukemia Myeloid Acute030220 oncology & carcinogenesisMyelodysplastic SyndromesFemalebusinessBusulfanVidarabine030215 immunologymedicine.drug
researchProduct